Pharmacological inhibitors of cyclin-dependent kinases.

@article{citeulike:1103934, abstract = {Cyclin-dependent kinases (CDKs) regulate the cell division cycle, apoptosis, transcription and differentiation in addition to functions in the nervous system. Deregulation of CDKs in various diseases has stimulated an intensive search for selective pharmacological inhibitors of these kinases. More than 50 inhibitors have been identified, among which >20 have been co-crystallized with CDK2. These inhibitors all target the ATP-binding pocket of the catalytic site of the kinase. The actual selectivity of most known CDK inhibitors, and thus the underlying mechanism of their cellular effects, is poorly known. Pharmacological inhibitors of CDKs are currently being evaluated for therapeutic use against cancer, alopecia, neurodegenerative disorders (e.g. Alzheimer's disease, amyotrophic lateral sclerosis and stroke), cardiovascular disorders (e.g. atherosclerosis and restenosis), glomerulonephritis, viral infections (e.g. HCMV, HIV and HSV) and parasitic protozoa (Plasmodium sp. and Leishmania sp.).}, address = {Station Biologique de Roscoff, CNRS, BP 74, 29682 Roscoff Cedex, Bretagne, France.}, author = {Knockaert, M. and Greengard, P. and Meijer, L. }, citeulike-article-id = {1103934}, issn = {0165-6147}, journal = {Trends Pharmacol Sci}, keywords = {cdk, cell, cycle, cyclin, inhibitor, kinase, pharmacology, small, transcription}, month = {September}, number = {9}, pages = {417--425}, posted-at = {2007-02-13 01:44:23}, priority = {2}, title = {Pharmacological inhibitors of cyclin-dependent kinases.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/12237154}, volume = {23}, year = {2002} }

TY - JOUR ID - citeulike:1103934 L3 - citeulike-article-id:1103934 N2 - Cyclin-dependent kinases (CDKs) regulate the cell division cycle, apoptosis, transcription and differentiation in addition to functions in the nervous system. Deregulation of CDKs in various diseases has stimulated an intensive search for selective pharmacological inhibitors of these kinases. More than 50 inhibitors have been identified, among which >20 have been co-crystallized with CDK2. These inhibitors all target the ATP-binding pocket of the catalytic site of the kinase. The actual selectivity of most known CDK inhibitors, and thus the underlying mechanism of their cellular effects, is poorly known. Pharmacological inhibitors of CDKs are currently being evaluated for therapeutic use against cancer, alopecia, neurodegenerative disorders (e.g. Alzheimer's disease, amyotrophic lateral sclerosis and stroke), cardiovascular disorders (e.g. atherosclerosis and restenosis), glomerulonephritis, viral infections (e.g. HCMV, HIV and HSV) and parasitic protozoa (Plasmodium sp. and Leishmania sp.). IS - 9 JF - Trends Pharmacol Sci SN - 0165-6147 AD - Station Biologique de Roscoff, CNRS, BP 74, 29682 Roscoff Cedex, Bretagne, France. EP - 425 TI - Pharmacological inhibitors of cyclin-dependent kinases. VL - 23 SP - 417 KW - cdk KW - cell KW - cycle KW - cyclin KW - inhibitor KW - kinase KW - pharmacology KW - small KW - transcription AU - Knockaert, M AU - Greengard, P AU - Meijer, L PY - 2002/09// UR - http://view.ncbi.nlm.nih.gov/pubmed/12237154 ER -